Scholar Rock

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Scholar Rock 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About SRRK

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. 

CEO
David L. Hallal
CEODavid L. Hallal
Employees
289
Employees289
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2012
Founded2012
Employees
289
Employees289

SRRK Key Statistics

Market cap
7.29B
Market cap7.29B
Price-Earnings ratio
-15.03
Price-Earnings ratio-15.03
Dividend yield
Dividend yield
Average volume
1.10M
Average volume1.10M
High today
High today
Low today
Low today
Open price
$52.51
Open price$52.51
Volume
0.00
Volume0.00
52 Week high
$58.49
52 Week high$58.49
52 Week low
$27.07
52 Week low$27.07

Stock Snapshot

With a market cap of 7.29B, Scholar Rock(SRRK) trades at $51.89. The stock has a price-to-earnings ratio of -15.03.

Scholar Rock(SRRK) stock opened on 2026-08-11 at $52.51. The price climbed to — and dipped to —.

Scholar Rock(SRRK) shares are trading with a volume of 0, against a daily average of 1.1M.

In the last year, Scholar Rock(SRRK) shares hit a 52-week high of $58.49 and a 52-week low of $27.07.

In the last year, Scholar Rock(SRRK) shares hit a 52-week high of $58.49 and a 52-week low of $27.07.

SRRK News

Benzinga 19h
Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule - Benzinga

...

Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule - Benzinga
TipRanks 4d
Scholar Rock to remove Catalent Indiana facility from apitegromab BLA

Scholar Rock (SRRK) announced that the FDA review of the apitegromab biologics license application, or BLA, for the treatment of children and adults with spinal...

Nasdaq 4d
Scholar Rock Q2 Earnings Call Highlights

Scholar Rock (NASDAQ:SRRK) said its resubmitted biologics license application for apitegromab remains on track for a U.S. Food and Drug Administration decision...

Scholar Rock Q2 Earnings Call Highlights

Analyst ratings

100%

of 17 ratings
Buy
100%
Hold
0%
Sell
0%

More SRRK News

TipRanks 4d
Scholar Rock: Buy Rating Reiterated as Apitegromab Advances Toward PDUFA; $65 Price Target Maintained

Andres Y. Maldonado, an analyst from H.C. Wainwright, reiterated the Buy rating on Scholar Rock Holding. The associated price target remains the same with $65.0...

Simply Wall St 5d
The Bull Case For Scholar Rock Could Change Following Dual-Track Apitegromab BLA Manufacturing Strategy

Scholar Rock reported second-quarter 2026 results showing a net loss of US$109.9 million and a basic loss per share of US$0.84, alongside updates on its apitegr...

The Bull Case For Scholar Rock Could Change Following Dual-Track Apitegromab BLA Manufacturing Strategy
TipRanks 5d
Scholar Rock Expands $200 Million At-The-Market Program

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

TipRanks 5d
Scholar Rock reports Q2 EPS (84c), consensus (84c)

“We are on the threshold of securing the world’s first ever regulatory approval of a myostatin inhibitor, which will also be the first ever muscle-targeted trea...

People also own

Based on the portfolios of people who own SRRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.